FindTrial
Sign In

KYV-101 anti-CD19 CAR-T cell therapy

BIOLOGICAL3 trials

Sponsors

Kyverna Therapeutics, Stanford University

Conditions

Lupus NephritisLupus Nephritis - WHO Class IIILupus Nephritis - WHO Class IVLupus Nephritis - World Health Organization (WHO) Class IIIMultiple SclerosisMultiple Sclerosis, Primary ProgressiveMultiple Sclerosis, Secondary Progressive

Phase 1

KYSA-1: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
TerminatedNCT05938725
Kyverna TherapeuticsLupus Nephritis, Lupus Nephritis - World Health Organization (WHO) Class III, Lupus Nephritis - WHO Class IV
Start: 2023-04-28End: 2026-05-29Updated: 2026-08-31
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis
RecruitingNCT06138132
Stanford UniversityMultiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Secondary Progressive
Start: 2024-04-10End: 2027-06-01Target: 12Updated: 2026-02-27
KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
TerminatedNCT06342960
Kyverna TherapeuticsLupus Nephritis, Lupus Nephritis - WHO Class III, Lupus Nephritis - WHO Class IV
Start: 2022-12-01End: 2025-12-22Updated: 2026-08-31

Related Papers

CAR T cells for multiple sclerosis: Engineering T cells to disrupt chronic B cell-driven neuroinflammation.
2025-10-261 citations
P95 First two US patients with lupus nephritis (LN) treated with anti-CD19 chimeric antigen receptor (CAR) T-cell therapy: preliminary results from the KYSA-1 phase 1, multicenter study of KYV-101
Poster presentations2024-03-015 citations